State-of-the-Art Meeting on Sex and Gender in Transplantation: The Female Perspective

Sex- and gender-based inequities in organ transplantation represent a critically relevant, yet under-appreciated aspect that impacts upon patient and graft outcomes. Biologic factors (sex), as well as psychological-, social-, and economic factors (gender) all contribute to these disparities. While such disparities are observed consistently worldwide, access to care and differences in allograft and patient outcomes by sex and gender differ between countries, emphasizing the necessity to engage the global community. Moreover, as in many other professional areas, gender disparities exist among professionals in transplantation science and medicine. To address the need for global recognition of the interplay between sex and gender in transplantation, and to define unmet needs, Anette Melk (Hannover Medical School), Bethany Foster (McGill University), Germaine Wong (University of Sydney), and Louise Lerminiaux (patient representative) initiated the international hybrid symposium “Sex and Gender in Transplantation: The Female Perspective”, which took place October 5th-7th 2022, in Hannover, Germany. The interdisciplinary symposium connected clinicians, researchers, and patients from around the globe. Instead of taking the traditional male perspective, efforts were made to ensure a female perspective and approach to both the content and organization of the symposium. The symposium had three aims. Firstly, we aimed to identify areas pertaining to sex and gender where more research is needed, with an emphasis on creating evidence to inform guidelines and policies. Second, we integrated patients’ perspectives and experience in the execution of patient-centred research. Finally, the symposium focused on achieving equity in access to careers in transplantation, defining metrics of success and strategies to accelerate progress in this area

Storytelling for impact: the creation of a storytelling program for patient partners in research

Abstract Storytelling is a powerful means to evoke empathy and understanding among people. When patient partners, which include patients, family members, caregivers and organ donors, share their stories with health professionals, this can prompt listeners to reflect on their practice and consider new ways of driving change in the healthcare system. However, a growing number of patient partners are asked to ‘share their story’ within health care and research settings without adequate support to do so. This may ultimately widen, rather than close, the gap between healthcare practitioners and people affected by chronic disease in this new era of patient and public involvement in research. To better support patient partners with storytelling in the context of a patient-oriented research network, Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network adapted an existing in-person storytelling workshop for patient educators within a hospital setting. The result is a 6-week virtual program called Storytelling for Impact, which guides patients, family members, caregivers and organ donors in developing impactful stories and sharing them at health care and research events, e.g., conferences. The online series of synchronous workshops is co-facilitated by story coaches, who are program alumni and Can-SOLVE CKD staff with trained storytelling experience. Each story follows a structure that includes a call to action, which aims to positively impact the priority-setting and delivery of care and research in Canada. The program has been a transformational process for many who have completed it, and numerous other health organizations have expressed interest in sharing this tool with their own patient partners. As result, we have also created an asynchronous online program that can be used by other interested parties outside our network. Patient partners who share their stories can be powerful mediators for inspiring changes in the health care and research landscape, with adequate structured support. We describe two novel programs to support patient partners in impactful storytelling, which are applicable across all health research disciplines. Additional resources are required for sustainability and scale up of training, by having alumni train future storytellers.Plain English summary Storytelling is a powerful means to evoke empathy and understanding among people. When patient partners share their stories with health professionals, this can prompt listeners to reflect on their practice and consider new ways of improving the healthcare system. However, as a growing number of patient partners are asked to ‘share their story’ within health care and research settings, there is often not enough tools and resources to support them in preparing their stories in a way that will be impactful for the audience members. Our kidney research network sought to create a novel in-person storytelling program to address this gap within our health research context. The result is a 6-week program called Storytelling for Impact, which guides patient partners—which includes patients, family members, caregivers and organ donors—in developing impactful stories and sharing them in a formal setting. The program is led by story coaches, who are patient partners and staff with trained storytelling experience. Participants are encouraged to include a call to action in their story, which aims to outline clear ways in which health professionals can facilitate positive change in health research or care. Many participants have described the program as transformational, and numerous other health organizations have expressed interest in sharing this tool with their own patient partners. As a result, we have also created a second online program that can be used by other interested parties outside our network. This paper highlights the adaptation process, content, participant feedback and next steps for the program

The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection

The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection (TCMR), borderline, and antibody-mediated rejection (ABMR). The main focus of kidney sessions was on how to address biopsies meeting criteria for CA TCMR plus borderline or acute TCMR. Recent studies on the clinical impact of borderline infiltrates were also presented to clarify whether the threshold for interstitial inflammation in diagnosis of borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing microvascular inflammation in the absence of C4d staining or detectable donor-specific antibodies; the potential value of molecular diagnostics in such cases and recommendations for use of the latter in the setting of solid organ transplantation are presented in the accompanying meeting report. Finally, several speakers discussed the capabilities of artificial intelligence and the potential for use of machine learning algorithms in diagnosis and personalized therapeutics in solid organ transplantation

Antibody-mediated Injury and Kidney Transplantation

We evaluated aspects of the pathogenesis, diagnosis, and prognosis of antibody-mediated injury secondary to anti-human leaukocyte antigen (HLA) antibodies in kidney transplant recipients and candidates. In a nested case-control study from a cohort of adult kidney transplant recipients, we found an increase in the odds of transplant glomerulopathy, a finding on kidney transplant biopsies suggestive of chronic antibody-mediated rejection, as a function of structural donor and recipient HLA class II incompatibility. We also re-evaluated the diagnostic schema of acute antibody-mediated rejection, and found that C4d, a complement degradation product suggestive of antibody-mediated injury to kidney allografts, exhibited modest agreement and sensitivity against histopathological features of acute antibody-mediated rejection and donor-specific anti-HLA antibody (DSA) assays. Prognostically, C4d was associated with inferior allograft survival compared with DSA or histopathology alone. Finally, we conducted a retrospective cohort study using the Scientific Registry of Transplant Recipients and found that the breadth of sensitization against anti-HLA antigens, measured as panel reactive antibodies (PRA), was an independent predictor of mortality in wait-listed kidney transplant candidates. These findings underscore the importance of anti-HLA antibodies to the outcomes of kidney transplant recipients and candidates, and suggest that anti-HLA antibodies may give rise to complement dependent and complement independent phenotypes of antibody-mediated injury. Whether avoidance of structural HLA incompatibility between donors and kidney transplant candidates and minimization of immune sensitization in wait-listed patients will improve outcomes of kidney transplant candidates and recipients, warrants further study.Ph.D.2016-11-18 00:00:0

Vergence Eye-Movements and Motion Visual Processing in Infantile Esotropia

Children with infantile esotropia (IET) demonstrate abnormal vergence eye-movements and motion processing. Abnormality of vergence manifests as suboptimal responses to disparity stimuli. Abnormal motion processing manifests as nasotemporal asymmetry in monocular pursuit and optokinetic nystagmus. Input from cortical motion processing centers is relayed to the vergence control system to allow accurate tracking of targets moving in depth

P32: a sex- and gender-sensitive model for evidence-based precision medicine: from knowledge generation to implementation in the field of kidney transplantation

Sapir-Pichhadze R, Oertelt-Prigione S. P32: a sex- and gender-sensitive model for evidence-based precision medicine: from knowledge generation to implementation in the field of kidney transplantation. Kidney International. 2023;103(4):674-685.Precision medicine emerged as a promising approach to identify suitable interventions for individual patients with a particular health concern and at various time points. Technology can enable the acquisition of increasing volumes of clinical and "omics" data at the individual and population levels and support advanced clinical decision making. However, to keep pace with evolving societal realities and developments, it is important to systematically include sex-and gender-specific considerations in the research process, from the acquisition of knowledge to implementation. Building on the foundations of evidence-based medicine and existing precision medicine frameworks, we propose a novel evidence-based precision medicine framework in the form of the P32 model, which considers individual sex-related (predictive [P1], preventive [P2], and personalized [P3] medicine) and gender-related (participatory [P4], psychosocial [P5], and percipient [P6] medicine) domains and their intersection with ethnicity, geography, and other demographic and social variables, in addition to population, community, and public dimensions (population-informed [P7], partnered with community [P8], and public-engaging [P9] medicine, respectively). Through its ability to contextualize and reflect on societal realities and developments, our model is expected to promote consideration of diversity, equity, and inclusion principles and, thus, enrich science, increase reproducibility of research, and ensure its social impact

Changing Paradigms in the Management of Rejection in Kidney Transplantation

Purpose of review: P4 medicine denotes an evolving field of medicine encompassing predictive, preventive, personalized, and participatory medicine. Using the example of kidney allograft rejection because of donor-recipient incompatibility in human leukocyte antigens, this review outlines P4 medicine’s relevance to the various stages of the kidney transplant cycle. Sources of information: A search for English articles was conducted in Medline via OvidSP (up to August 18, 2016) using a combination of subject headings (MeSH) and free text in titles, abstracts, and author keywords for the concepts kidney transplantation and P4 medicine. The electronic database search was expanded further on particular subject headings. Findings: Available histocompatibility methods exemplify current applications of the predictive and preventive domains of P4 medicine in kidney transplant recipients’ care. Pharmacogenomics are discussed as means to facilitate personalized immunosuppression regimens and promotion of active patient participation as a means to improve adherence. Limitations: For simplicity, this review focuses on rejection. P4 medicine, however, should more broadly address health concerns in kidney transplant recipients, including competing outcomes such as infections, malignancies, and cardiovascular disease. This review highlights how biomarkers to evaluate these competing outcomes warrant validation and standardization prior to their incorporation into clinical practice. Implications: Consideration of all 4 domains of the P4 medicine framework when caring for and/or studying kidney transplant recipients has the potential of increasing therapeutic efficiency, minimizing adverse effects, decreasing health care costs, and maximizing wellness. Technologies to gauge immune competency, immunosuppression requirements, and early/reversible immune-mediated injuries are required to optimize kidney transplant care